Loading…
Biocon (BIOCON)₹368.50+0.34%Pharmaceuticals
At the end of the Jun 2026 quarter, Biocon's shareholders were: promoters 44.73%, FIIs 8.18%, DIIs 23.32%, government 0.05%, public 23.67%, others 0.05%. Promoter holding is down 0.23 percentage points from 44.96% a quarter earlier. FII holding is up 2.10 percentage points from 6.08% a year earlier. 0.00% of promoter shares were pledged. It had 3,92,796 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 60.69% | 60.69% | 60.69% | 60.69% | 60.69% | 60.69% | 60.69% | 54.50% | 54.50% | 54.50% | 44.96% | 44.73% |
| FIIs | 8.01% | 6.59% | 5.67% | 5.94% | 5.97% | 5.70% | 5.71% | 6.08% | 6.65% | 7.43% | 7.56% | 8.18% |
| DIIs | 14.07% | 14.50% | 13.68% | 14.28% | 14.43% | 15.35% | 15.72% | 22.82% | 22.05% | 21.66% | 24.00% | 23.32% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% | 0.03% | 0.05% | 0.05% |
| Public | 16.84% | 17.89% | 19.64% | 18.81% | 18.66% | 18.04% | 17.67% | 16.42% | 16.63% | 16.26% | 23.34% | 23.67% |
| Others | 0.39% | 0.33% | 0.32% | 0.28% | 0.25% | 0.22% | 0.21% | 0.18% | 0.14% | 0.12% | 0.09% | 0.05% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 4,15,007 | 4,34,298 | 4,70,217 | 4,43,471 | 4,39,462 | 4,27,665 | 4,24,257 | 4,28,091 | 4,13,152 | 3,94,242 | 3,86,557 | 3,92,796 |
| Holder | Category | Jun 2026 | Change (pp) |
|---|---|---|---|
| Kiran Mazumdar Shaw | Promoter | 29.68% | −0.17 |
| Glentec International | Promoter | 14.52% | −0.07 |
| Magnum Hybrid Long Short Fund | DII | 8.72% | New |
| Mylan Inc. | Public | 5.63% | −0.03 |
| Life Insurance Corporation Of India - 2 | DII | 3.70% | New |
| Serum Institute Life Sciences Private Limited | Public | 3.39% | −0.02 |
| Isif Equity Ex-Top 100 Long-Short Fund | DII | 1.47% | New |
| Kotak Mahindra Trustee Co Ltd A/C Kotak Nifty Midc | DII | 1.30% | New |
| Activ Pine Llp | Public | 1.07% | −0.01 |
| Hdfc Life Insurance Company Limited | DII | 1.02% | New |
| Ravi Rasendra Mazumdar | Promoter | 0.33% | 0.00 |
| Dev Mazumdar | Promoter | 0.06% | 0.00 |
| Sbi Large & Midcap Fund | DII | Exited | — |
| Lici New Pension Plus Growth Fund | DII | Exited | — |
| Icici Prudential Innovation Fund | DII | Exited | — |
| Mirae Asset Nifty Midcap 150 Etf | DII | Exited | — |
| Nippon Life India Trustee Ltd- A/C Nippon India Vi | DII | Exited | — |
| Kotak Large & Midcap Fund | DII | Exited | — |
Promoters held 44.73% of Biocon at the end of the Jun 2026 quarter, down 9.77 percentage points from 54.50% a year earlier.
In the Jun 2026 quarter, foreign institutional investors (FIIs) held 8.18% (up 0.62 percentage points from 7.56% a quarter earlier) and domestic institutions (DIIs) held 23.32% (down 0.68 percentage points from 24.00% a quarter earlier).
No. The Jun 2026 filing shows no pledged promoter shares.
Biocon had 3,92,796 shareholders at the end of the Jun 2026 quarter, against 4,28,091 a year earlier.
Magnum Hybrid Long Short Fund (DII) held 8.72% at the end of the Jun 2026 quarter, the largest named holding outside the promoter group.